Format

Send to

Choose Destination
Expert Opin Pharmacother. 2014 Apr;15(5):711-6. doi: 10.1517/14656566.2014.889116. Epub 2014 Feb 11.

New antiviral agents for the treatment of hepatitis C: ABT-450.

Author information

1
University of Miami, Miller School of Medicine, Division of Gastroenterology , 1120 NW 14th Street, Suite 310E, Miami, FL 33136 , USA +1 305 243 8644 ; +1 305 243 3762 ; acarrionmonsalve@med.miami.edu.

Abstract

INTRODUCTION:

Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non-structural 3/4A protease that has been studied in combination with several agents, allowing shorter duration of therapy and interferon-free/ribavirin-free all-oral regimens. Preliminary data from studies evaluating these new regimens are impressive with sustained virological response (SVR) rates of 88 - 100% after 12 weeks of therapy in patients with previously untreated HCV genotype 1 infection. SVR rates in treatment-experienced patients are also encouraging.

AREAS COVERED:

Efficacy and tolerability of antiviral regimens containing ABT-450 boosted with ritonavir (ABT-450/r). Results from published studies and abstracts from recent meetings are presented.

EXPERT OPINION:

Newer direct-acting antiviral agents such as ABT-450 promise effective and durable suppression of HCV with interferon/ribavirin-free all-oral regimens. This agent also allows for shorter duration of treatment and has tolerable side effects. Results of clinical trials including a broader spectrum of individuals with HCV infection are eagerly awaited.

PMID:
24517400
DOI:
10.1517/14656566.2014.889116
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center